Continue reading this on our app for a better experience

Open in App
Home News Covid-19

Pfizer/BioNTech booster shot restores full Covid protection

Bloomberg
Bloomberg • 2 min read
Pfizer/BioNTech booster shot restores full Covid protection
"Booster vaccinations could play an important role in sustaining pandemic containment and a return to normalcy."
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Pfizer Inc. and BioNTech SE said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely.

A booster was 95.6% effective against symptomatic Covid in the study, which followed 10,000 people aged 16 and older, the companies said on Thursday.

Pfizer shares were 0.9% higher in premarket U.S. trading, with BioNTech gaining 1.3% in Frankfurt.

“We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,” Pfizer Chief Executive Officer Albert Bourla said in a statement. The companies said they’ll share the data with health authorities in the U.S., Europe and elsewhere.

Regulators have wrestled with how widely to use boosters as the fast-spreading delta variant drives infection rates up. Some countries, such as Israel, are using boosters widely. Many others -- including the U.S. and much of Europe -- have thus far come down on the side of a third dose for the elderly and other high-risk individuals. Exactly where to draw the line on who is high-risk has also been a matter of debate.

Half the trial participants got a booster, with five cases in that group over an average follow-up period of two and a half months. There were 109 cases in the group randomly assigned a placebo shot. The booster was just as safe as the original two-dose vaccine.

The trial results show that “booster vaccinations could play an important role in sustaining pandemic containment and a return to normalcy,” BioNTech CEO Ugur Sahin said.

Trial participants got a booster an average of 11 months after their second dose of the vaccine. They were an average of 53 years old, with slightly under one-quarter of the group older than age 65. Efficacy of the third shot was consistent across age groups and among people with pre-existing conditions, the companies said.

Photo: Bloomberg

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.